Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 3/2015

01.03.2015 | Original Article – Clinical Oncology

Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006

verfasst von: Marco Johannes Battista, Marcus Schmidt, Nicole Rieks, Isabel Sicking, Stefan Albrich, Michael Eichbaum, Heinz Koelbl, Peter Mallmann, Gerald Hoffmann, Eric Steiner

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In 2013, 2009 and 2006, the Arbeitsgemeinschaft Gynäkologische Onkologie evaluated the therapeutic approaches for endometrial carcinoma and the adherence to their guideline in Germany. Here, the adjuvant treatment decisions were presented.

Methods

A questionnaire was developed and sent to all 682 German gynecological departments in 2013 (775 in 2009 and 500 in 2006, respectively). The results of the questionnaires were compared with the recommendations of the guideline and with each other using Fisher’s exact test.

Results

Responses were available in 40.0 % in 2013, 33.3 % in 2009 and 35.8 % in 2006. Participants recommended external beam radiotherapy (EBRT) in 13 out of 16 requested stages and vaginal brachytherapy (VBT) in only 10 out of 16 requested stages as suggested by the guideline. Comparing the results of 2013 with 2009, less participants used EBRT and VBT in 7 out of 16 and in 6 out of 16 requested stages, respectively. Conversely, more participants offered adjuvant chemotherapy (CT) in 2013 (90.4 %) compared to 61.9 % in 2009 (p < 0.001) and 48.8 % in 2006 (p < 0.001), respectively. However, the stage-adjusted recommendations of CT were not in line with the guideline in 11 out of 15 requested stages. In total, 77.3 % of the participants use a multiple drug schedule with a platinum and a taxane compound.

Conclusions

The results suggest non-adherence to the guideline concerning the stage-adjusted use of VBT and CT in endometrial carcinoma. These findings emphasize great uncertainties and the need of more clarifying trials. Furthermore, a shift from radiotherapy toward CT is observable.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Ackerman I, Malone S, Thomas M, Franssen E, Balogh J, Dembo A (1996) Endometrial carcinoma-relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol 60:177–183CrossRefPubMed Ackerman I, Malone S, Thomas M, Franssen E, Balogh J, Dembo A (1996) Endometrial carcinoma-relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol 60:177–183CrossRefPubMed
Zurück zum Zitat Akram T, Maseelall P, Fanning J (2005) Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 192:1365–1367CrossRefPubMed Akram T, Maseelall P, Fanning J (2005) Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 192:1365–1367CrossRefPubMed
Zurück zum Zitat Battista MJ, Steiner E, Rieks N, Steetskamp J, Seeger A, Sicking I et al (2013) Nationwide analysis on surgical staging procedures and systemic treatment for patients with endometrial cancer in Germany. Int J Gynecol Cancer 23:105–112CrossRefPubMed Battista MJ, Steiner E, Rieks N, Steetskamp J, Seeger A, Sicking I et al (2013) Nationwide analysis on surgical staging procedures and systemic treatment for patients with endometrial cancer in Germany. Int J Gynecol Cancer 23:105–112CrossRefPubMed
Zurück zum Zitat Battista MJ, Schmidt M, Rieks N, Steetskamp J, Sicking I, Lebrecht A et al (2014) Nationwide analysis on surgical procedures for patients with endometrial cancer in Germany: results of the AGO pattern of care studies from the years 2013, 2009, and 2006. J Cancer Res Clin Oncol. doi:10.1007/s00432-014-1755-7 Battista MJ, Schmidt M, Rieks N, Steetskamp J, Sicking I, Lebrecht A et al (2014) Nationwide analysis on surgical procedures for patients with endometrial cancer in Germany: results of the AGO pattern of care studies from the years 2013, 2009, and 2006. J Cancer Res Clin Oncol. doi:10.​1007/​s00432-014-1755-7
Zurück zum Zitat Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H et al (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373:137–146CrossRefPubMed Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H et al (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373:137–146CrossRefPubMed
Zurück zum Zitat Creasman W (2009) Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105:109CrossRefPubMed Creasman W (2009) Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105:109CrossRefPubMed
Zurück zum Zitat Creutzberg CL, Van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial Carcinoma. Lancet 355:1404–1411CrossRefPubMed Creutzberg CL, Van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial Carcinoma. Lancet 355:1404–1411CrossRefPubMed
Zurück zum Zitat Emons G, Kimmig R (2008) Interdisziplinäre S2 k-Leitlinie für die Diagnostik und Therapie des Endometriumkarzinoms. In: Horn LC, Beckmann MW (eds) Leitlinien zum Zervixkarzinom, zum Endometriumkarzinom und zu den Trophoblasttumoren. Zuckschwerdt, München, pp 73–126 Emons G, Kimmig R (2008) Interdisziplinäre S2 k-Leitlinie für die Diagnostik und Therapie des Endometriumkarzinoms. In: Horn LC, Beckmann MW (eds) Leitlinien zum Zervixkarzinom, zum Endometriumkarzinom und zu den Trophoblasttumoren. Zuckschwerdt, München, pp 73–126
Zurück zum Zitat Hasbini A, Haie-Meder C, Morice P, Chirat E, Duvillard P, Lhommé C et al (2002) Outcome after salvage radiotherapy (brachytherapy ± external) in patients with a vaginal recurrence from endometrial carcinomas. Radiother Oncol 65:23–28CrossRefPubMed Hasbini A, Haie-Meder C, Morice P, Chirat E, Duvillard P, Lhommé C et al (2002) Outcome after salvage radiotherapy (brachytherapy ± external) in patients with a vaginal recurrence from endometrial carcinomas. Radiother Oncol 65:23–28CrossRefPubMed
Zurück zum Zitat Hogberg T, Signorelli M, De Oliveira CF, Fossati R, Lissoni AA, Sorbe B et al (2010) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer 46:2422–2431CrossRefPubMedCentralPubMed Hogberg T, Signorelli M, De Oliveira CF, Fossati R, Lissoni AA, Sorbe B et al (2010) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer 46:2422–2431CrossRefPubMedCentralPubMed
Zurück zum Zitat Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C et al (2001) Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19:4048–4053PubMed Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C et al (2001) Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19:4048–4053PubMed
Zurück zum Zitat Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol 92:744–751CrossRefPubMed Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol 92:744–751CrossRefPubMed
Zurück zum Zitat Koh W-J, Greer BE, Abu-Rustum NR (2014) Uterine neoplasms NCCN clinical practice guidelines in oncology. www.nccn.org. Accessed 4 April 2014 Koh W-J, Greer BE, Abu-Rustum NR (2014) Uterine neoplasms NCCN clinical practice guidelines in oncology. www.​nccn.​org. Accessed 4 April 2014
Zurück zum Zitat Kuoppala T, Mäenpää J, Tomas E, Puistola U, Salmi T, Grenman S et al (2008) Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs sequential chemo-radiotherapy. Gynecol Oncol 110:190–195CrossRefPubMed Kuoppala T, Mäenpää J, Tomas E, Puistola U, Salmi T, Grenman S et al (2008) Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs sequential chemo-radiotherapy. Gynecol Oncol 110:190–195CrossRefPubMed
Zurück zum Zitat Lee CM, Szabo A, Shrieve DC, Macdonald OK, Tward JD, Skidmore TB et al (2007) Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: a surveillance, epidemiology, and end results population study. Cancer 110:2092–2100CrossRefPubMed Lee CM, Szabo A, Shrieve DC, Macdonald OK, Tward JD, Skidmore TB et al (2007) Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: a surveillance, epidemiology, and end results population study. Cancer 110:2092–2100CrossRefPubMed
Zurück zum Zitat Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G et al (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271CrossRefPubMedCentralPubMed Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G et al (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271CrossRefPubMedCentralPubMed
Zurück zum Zitat Morrow CP, Bundy BN, Homesley HD, Creasman WT, Hornback N, Kurman R et al (1990) Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a gynecologic oncology group study. Gynecol Oncol 36:166–171CrossRefPubMed Morrow CP, Bundy BN, Homesley HD, Creasman WT, Hornback N, Kurman R et al (1990) Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a gynecologic oncology group study. Gynecol Oncol 36:166–171CrossRefPubMed
Zurück zum Zitat Naumann RW, Coleman RL (2007) The use of adjuvant radiation therapy in early endometrial cancer by members of the society of gynecologic oncologists in 2005. Gynecol Oncol 105:7–12CrossRefPubMed Naumann RW, Coleman RL (2007) The use of adjuvant radiation therapy in early endometrial cancer by members of the society of gynecologic oncologists in 2005. Gynecol Oncol 105:7–12CrossRefPubMed
Zurück zum Zitat Naumann RW, Higgins RV, Hall JB (1999) The use of adjuvant radiation therapy by members of the society of gynecologic oncologists. Gynecol Oncol 75:4–9CrossRefPubMed Naumann RW, Higgins RV, Hall JB (1999) The use of adjuvant radiation therapy by members of the society of gynecologic oncologists. Gynecol Oncol 75:4–9CrossRefPubMed
Zurück zum Zitat Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, Van der Steen-Banasik EM et al (2009) Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 27:3547–3556CrossRefPubMed Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, Van der Steen-Banasik EM et al (2009) Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 27:3547–3556CrossRefPubMed
Zurück zum Zitat Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375:816–823CrossRefPubMed Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375:816–823CrossRefPubMed
Zurück zum Zitat Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 24:36–44CrossRefPubMed Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 24:36–44CrossRefPubMed
Zurück zum Zitat Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M (2008) Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 18:803–808CrossRefPubMed Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M (2008) Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 18:803–808CrossRefPubMed
Zurück zum Zitat Sorbe B, Nordström B, Mäenpää J, Kuhelj J, Kuhelj D, Okkan S et al (2009) Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 19:837–838CrossRef Sorbe B, Nordström B, Mäenpää J, Kuhelj J, Kuhelj D, Okkan S et al (2009) Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 19:837–838CrossRef
Zurück zum Zitat Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B (2012) External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma—a prospective randomized study. Int J Radiat Oncol Biol Phys 82:1249–1255CrossRefPubMed Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B (2012) External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma—a prospective randomized study. Int J Radiat Oncol Biol Phys 82:1249–1255CrossRefPubMed
Zurück zum Zitat Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S et al (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group Study. Gynecol Oncol 108:226–233CrossRefPubMed Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S et al (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group Study. Gynecol Oncol 108:226–233CrossRefPubMed
Zurück zum Zitat Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N et al (2009) Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese gynecologic oncology group. Gynecol Oncol 115:456–459CrossRefPubMed Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N et al (2009) Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese gynecologic oncology group. Gynecol Oncol 115:456–459CrossRefPubMed
Zurück zum Zitat Wright JD, Lewin SN, Barrena Medel NI, Sun X, Burke WM, Deutsch I et al (2011) Endometrial cancer in the oldest old: tumor characteristics, patterns of care, and outcome. Gynecol Oncol 122:69–74CrossRefPubMed Wright JD, Lewin SN, Barrena Medel NI, Sun X, Burke WM, Deutsch I et al (2011) Endometrial cancer in the oldest old: tumor characteristics, patterns of care, and outcome. Gynecol Oncol 122:69–74CrossRefPubMed
Metadaten
Titel
Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006
verfasst von
Marco Johannes Battista
Marcus Schmidt
Nicole Rieks
Isabel Sicking
Stefan Albrich
Michael Eichbaum
Heinz Koelbl
Peter Mallmann
Gerald Hoffmann
Eric Steiner
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1834-9

Weitere Artikel der Ausgabe 3/2015

Journal of Cancer Research and Clinical Oncology 3/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.